Canaccord analyst Tania Armstrong-Whitworth downgraded Knight Therapeutics (KHTRF) to Hold from Buy with a C$6.50 price target
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KHTRF:
- Knight Therapeutics Achieves Record Revenues and Expands Product Approvals
- Knight Therapeutics reports FY24 EPS C$0.04 vs. (C$0.16) last year
- Knight Therapeutics sees FY25 revenue C$390M-C$405M
- Knight Therapeutics (KHTRF) Q4 Earnings Cheat Sheet
- Knight Therapeutics price target raised to C$8 from C$7.50 at Raymond James
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue